Dr. Xavier Montalban receives the ICS Hospitals Research Career Award 2023

Xavier Montalban, Director of the Multiple Sclerosis Center of Catalonia (Cemcat), Head of the Neurology Service of the Vall d'Hebron University Hospital and of the Clinical Neuroimmunology research group of the Vall d'Hebron Research Institute, as well as Vice-President of the Multiple Sclerosis Foundation, has been awarded for his significant contribution to the development of research within the Catalan Institute of Health.

A single dose of attenuated vaccines could protect multiple sclerosis patients before starting immunosuppressive therapy

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment. The study was carried out by René Carvajal, Mar Tintoré and Susana Otero-Romero, researchers at Cemcat, led by Xavier Montalbán, and the Vall d'Hebron University Hospital.

Dr. Montalban led a study that proves the efficacy of a drug in primary progressive multiple sclerosis

The New Journal of Medicine has published the positive results of Ocrelizumab in the treatment of primary progressive multiple sclerosis (PPMS). Dr. Xavier Montalban, head of the Service of Neuroimmunology of Vall d’Hebron and director of Cemcat, is the corresponding author of this article and leads the Scientific Board of the phase III clinical trial ORATORIO that has risen out these results. The Sclerosis Multiple Centre of Catalonia (known as Cemcat in Catalan) has participated in this clinical trial.

Cemcat has provided training to 40 profesionals from the Middle East

More than 40 international profesionals have received specialized training in Multiple Sclerosis during the month of October at the Cemcat. Most of them were neurologists and nurses from the Middle East who were interested in expanding their knowledge on the disease.

ECTRIMS 2016 and developments in MS: How Cemcat participates

Cemcat’s team participates in the ECTRIMS 2016 congress with a high number of informs/communications (more than 25), earning its place amongst the five most productive groups worldwide. Dr. Xavier Montalban, Director of Cemcat and president of ECTRIMS 2016, pronounces the inaugural conference which focuses on the diagnosis and customized treatment of Multiple Sclerosis. The congress is the most important in the field of MS and it brings more than 9000 profesionals together.